COMMUNIQUÉS West-GlobeNewswire

Why Is Weight Loss Different During Menopause? Common Myths Debunked
15/10/2026
Myth: Menopause weight gain is inevitable. Truth: Acceleration is not inevitable. Body composition science addresses the underlying shift. Myth: Eating less and moving more is enough in midlife. Truth: Without a [...]
Eclipse Life Sciences Announces Positive Topline Results from Phase 2 BETTIS-1 Study Evaluating EC-104 for Diabetic Macular Edema (DME)
15/10/2026
RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eclipse Life Sciences, Inc. , a privately held clinical-stage biopharmaceutical company developing next-generation therapies for retinal diseases, today [...]
R1 Therapeutics to present Phase 2b trial-in-progress poster for AP306 at ASN Kidney Week 2026
15/10/2026
Poster will outline the design of R1’s ongoing global Phase 2b trial evaluating AP306 in patients with hyperphosphatemia AP306 is a potential first-in-class, oral, non-binder small molecule designed to inhibit all three [...]
OMass Therapeutics Announces $310 Million Series C Financing to Advance Portfolio of Small Molecule Therapeutics in Endocrinology and Immunology
15/10/2026
Financing co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with strong participation from additional new and existing investors Proceeds to advance MC2 receptor antagonist OMS1620 through [...]
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
15/10/2026
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes The Phase 1 trial will assess the safety and clinical [...]
Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
15/10/2026
Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 Substantial regression was observed in lesions not directly injected with KB113, consistent with [...]
Profusa Receives ISO 13485:2016 Certificate from GMED
15/10/2026
Providing a Foundational Quality Management System (QMS) for Commercialization Certificate issued by GMED, an EU MDR notified body, following the positive certification decision previously announced ISO 13485 [...]
Correction: DXS International PLC (AQSE: DXSP) NHS Announces £838m GP IT Framework
15/10/2026
15 October 2026 DXS INTERNATIONAL PLC (AQSE: DXSP) NHS Announces £838m GP IT Framework DXS International plc ( AQSE: DXSP ), the UK healthcare technology provider, welcomes the announcement from NHS England which has [...]
NHS Announces £838m GP IT Framework
15/10/2026
15 October 2026 DXS INTERNATIONAL PLC (AQSE: DXSP) NHS Announces £838m GP IT Framework DXS International plc ( AQSE: DXSP ), the UK healthcare technology provider, welcomes the announcement from NHS England which has [...]
invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal
15/10/2026
invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal Publication in Molecular Therapy Oncology reports Phase 1 data from 17 patients with advanced, treatment- [...]
EXIT-CVD research consortium launches clinical studies to transform cardiovascular care across Europe
15/10/2026
October 15, 2026 Five-year research project unites 42 public and private partners across 17 countries to conduct 22 clinical studies involving 14,000+ patients; first patients will be enrolled this month Project aims to [...]
Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325
15/10/2026
MTX325 is a first-in-class, highly potent, orally bioavailable, brain-penetrant USP30 inhibitor designed to modify the course of Parkinson’s by improving mitochondrial control Phase 1b ‘MTX325-101’ study – taking place [...]
iOnctura appoints Paul Sekhri as Chair of its Board of Directors
15/10/2026
Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization Appointment comes as iOnctura prepares for late-stage [...]
DaltonTx awarded grant to accelerate AI-powered tuberculosis drug discovery
15/10/2026
Funding from the Gates Foundation supports development of open-access AI models, workflows and datasets to help researchers identify new tuberculosis (TB) targets for faster and more cost-effective drug discovery [...]
OMass Therapeutics Announces $310 Million Series C Financing to Advance Portfolio of Small Molecule Therapeutics in Endocrinology and Immunology
15/10/2026
Financing co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with strong participation from additional new and existing investors Proceeds to advance MC2 receptor antagonist OMS1620 through [...]
OSE Immunotherapeutics to Present at Chardan’s 10th Annual Healthcare Conference
15/10/2026
Nantes, France, October 15, 2026 – 7:30am CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and [...]
OSE Immunotherapeutics présentera lors de la 10ème Chardan Annual Healthcare Conference
15/10/2026
Nantes, France, 15 octobre 2026 – 7h30 CEST – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnémo: OSE) , une société de biotechnologie au stade clinique développant des thérapies first-in-class en immuno-oncologie [...]
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
15/10/2026
October 15, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22, [...]
IBA selected to support the US expansion of a leading radiopharmaceutical producer with an order for 12 Cyclone® KIUBE systems
15/10/2026
IBA is preferred supplier for a 12-system national PET radiopharmaceutical production network, securing capacity ahead of demand across diagnostics and theranostics Louvain-la-Neuve, Belgium – October 15, 2026, 7 a.m [...]

Pages